Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens

Future Virology

Volumn 5, Issue 5, 2010, Pages 545-554

  Morrison, Trudy G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

human vaccines; Newcastle disease virus; vaccine platform; veterinary vaccines; virus like particles

Indexed keywords

NEWCASTLE DISEASE VACCINE;

DNA REPLICATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; NEWCASTLE DISEASE; NONHUMAN; POULTRY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROVOCATION TEST; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS LIKE AGENT;

AVES; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 77957299929     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.50     Document Type: Review

References (59)

1. Chong YL, Padhi A, Hudson PJ, Poss M: The effect of vaccination on the evolution and population dynamics of avian paramyxovirus-1. PLoS Pathog. 6(4), e1000872 (2010).
2. Simmonds P: Recombination and selection in the evolution of picornaviruses and other mammalian positive-stranded RNA viruses. J. Virol. 80, 11124-11140 (2006).
3. Draper SJ, Heeney JL: Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Micro. 8(1), 62-73 (2010).
4. Bukreyev A, L Yang, Zaki SR et al.: A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80, 2267-2279 (2006).
5. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A: Long term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340, 174-182 (2006).
6. Bangari D, Mittal S: Current strategies and future directions eluding adenovirus vector immunity. Curr. Gene Ther. 6, 215-226 (2006).
7. Graham BS, Crowe JE: Immunization against viral diseases. In: Fields Virology. Knipe DM, Howley PM Eds. Lippincott Williams & Wilkins, PA, USA 487-538 (2007).
8. Kang S-M, Song J-M, Quan F-S, Compans RW: Influenza vaccines based on virus-like particles. Virus Res. 143(2), 140-146 (2009). □□ Excellent review of influenza virus-like particles (VLPs) as human vaccines.
9. Wood J, Robertson J: From lethal virus to lifesaving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842-847 (2004).
10. Griffin D: Measles virus. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 1551-1586 (2007).
11. Littel-van den Hurk SD, Mapletoft JW, Arsic N, Kovacs-Nolan J: Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev. Med. Virol. 17, 5-34 (2007).
12. Kutzler MA, Weiner DB: DNA vaccines: ready for prime time? Nat. Rev. Genet. 9(10), 776-788 (2008).
13. Liu MA, Ulmer JB: Human clinical trials of plasmid DNA vaccines. Advance Genetics 55, 25-40 (2005).
14. Elliott MB, Chen T, Terio NB et al.: αvirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144 (2007).
15. Mok H, Lee S, Utley TJ et al.: Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81, 13710-13722 (2007).
16. Seligman SJ, Gould EA: Live flavivirus vaccines: reasons for caution. Lancet 363, 2073-2075 (2004).
17. Jennings GT, Bachmann MF: The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521-536 (2008). □□ Excellent review of the status of VLP vaccines.
18. Young KR, McBurney SP, Karkhanis LU, Ross TM: Virus-like particles: designing an effective AIDS vaccine. Methods 40(1), 98-117 (2006).
19. Warfeld KL, Bosio CM, Welcher BC et al.: Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl Acad. Sci. USA 100(26), 15889-15894 (2003).
20. Sun Y, Carrion R Jr, Ye L et al.: Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383(1), 12-21 (2009). □ Recent description of Ebola virus VLPs as a vaccine candidate.
21. Bright RA, Carter DM, Daniluk S et al.: Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007). □ Comparison of immune responses in mice to influenza VLPs, whole inactivated virions and soluble HA protein.
22. Mahmood K, Bright RA, Mytle N et al.: H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393-5399 (2008).
23. Perrone LA, Ahmad A, Veguilla V et al.: Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83(11), 5726-5734 (2009).
24. Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA: A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4, 6032 (2009). □ Recent description of influenza VLPs as a vaccine candidate for seasonal influenza.
25. Akahata W, Yang Z-Y, Andersen H et al.: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16(3), 334-338 (2010). □ Description of Chikungunya virus VLPs as a vaccine candidate.
26. Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 42(2), 259-277 (2005). □□ Excellent review of different VLPs based on the HIV gag and immune responses to these VLPs.
27. Elmowalid GA, Qiao M, Jeong S-H et al.: Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427-8432 (2007). □ Description of the effectiveness of HCV VLPs as a vaccine candidate.
28. Grgacic EVL, Anderson DA: Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006).
29. Ludwig C, Wagner R: Virus-like particles - universal molecular toolboxes. Curr. Opin. Biotechnol. 18(6), 537-545 (2007).
30. Kuate S, Stahl-Hennig C, Stoiber H et al.: Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 351(1), 133-144 (2006).
31. Haynes JR, Dokken L, Wiley JA et al.: Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4), 530-541 (2009).
32. Li M, Schmitt PT, Li Z, McCrory TS, He B, Schmitt AP: Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles. J. Virol. 83(14), 7261-7272 (2009).
33. Halsey RJ, Tanzer FL, Meyers A et al.: Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res. 133(2), 259-268 (2008).
34. Fu T-M, Grimm KM, Citron MP et al.: Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27(9), 1440-1447 (2009).
35. Karron RA, Collins PL: Parainfluenza viruses. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 1497-1526 (2007).
36. Lamb RA, Parks GD: Paramyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM, Griffn de et al. (Eds). Lippincott Williams & Wilkins, PA, USA 1450-1496 (2007).
37. Collins PL, Crowe JE: Respiratory Syncytial Virus and Metapneumovirus. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA (2007).
38. Schmitt AP, Leser GP, Waning DL, Lamb RA: Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J. Virol. 76, 3952-3964 (2002).
39. Takimoto T, Murti KG, Bousse T, Scroggs RA, Portner A: Role of matrix and fusion proteins in budding of Sendai virus. J. Virol. 75, 11384-11391 (2001).
40. Coronel EC, Murti KG, Takimoto T, Portner A: Human parainfluenza virus type I matrix and nucleocapsid genes transiently expressed in mammalian cells induce release of virus-like particles containing nucleocapsid structures. J. Virol. 73, 7035-7038 (1999).
41. Sugahara F, Uchiyama T, Watanabe H et al.: Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein. Virology 325, 1-10 (2004).
42. Cicncanelli MJ, Basler CF: Mutation of the YMXL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. Virol. J. 80, 12070-12078 (2006).
43. Patch JR, Crameri G, Wang LF, Eaton BT, Broder CC: Quantitative analysis of Nipah virus proteins released as virus-like particles reveals a central roll for the matrix protein. Virol. J. 4, 1-12 (2007).
44. McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG: Assembly and biological and immunological properties of Newcastle disease virus-like particles. J. Virol. 84, 4513-4523 (2010).
45. Pantua HD, McGinnes LW, Peeples ME, Morrison TG: Requirements for the assembly and release of Newcastle disease virus-like particles. J. Virol. 80, 11062-11073 (2006).
46. Murawski MR, McGinnes LW, Finberg RW et al.: Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice with no evidence of immunopathology. J. Virol. 84, 1110-1123 (2010).
47. Alexander DJ: Newcastle disease, pneumovirus infection, and other paramyxoviruses. In: Diseases of Poultry. Saif YM, Fadly AM, Glisson JR, McDougald LR, Nolan KL, Swayne de (Eds). Wiley, Oxford, UK 63-88 (2008).
48. Kapczynski DR, King DJ: Protection of chickens against overt clinical disease and determination of virual shedding following vaccinaion with commercially available Newcastle disease virus vaccines upon challenge with highly virulent virus from the California 2002 exotic Newcastle disease outbreak. Vaccine 23, 3424-3433 (2005).
49. Delgado MF, Coviello S, Monsalvo AC et al.: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34-41 (2009).
50. Freeman AI, Zakay-Rones Z, Gomori JM et al.: PhaseI/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther., 13, 221-228 (2006).
51. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI: Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23(10), 523-529 (2005).
52. Kost TA, Condreay JP, Jarvis DL: Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotech. 23(5), 567-575 (2005).
53. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50), 5751-5759 (2005).
54. Power UF: Respiratory syncytial virus (RSV) vaccines - two steps back for one leap forward. J. Clin. Virol. 41, 38-44 (2008).
55. Schmidt MR, Appel MC, Giassi LJ, Greiner DL, Shultz LD, Woodland RT: Human BLyS facilitates engraftment of human PBL derived B cells in immunodefcient mice. PLoS One 3(9), e3192 (2008).
56. Legrand N, Ploss A, Balling R et al.: Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6(1), 5-9 (2009).
57. Shultz LD, Ishikawa F, Greiner DL: Humanized mice in translational biomedical research. Nat. Rev. 7(2), 118-130 (2007).
58. Miyazaki J, Takaki S, Araki K et al.: Expression vector system based on the chicken β-actin promoter directs efficient production of interleukin 5. Gene 79, 269-277 (1989).
59. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).